Key Points
Boston Scientific (NYSE: BSX) shares have underperformed significantly this year, declining by more than 50% year-to-date. The company has repeatedly revised its growth forecasts downward, contributing to investor skepticism. However, despite market concerns, analyst sentiment remains largely positive, suggesting potential for recovery in the near term.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Boston Scientific and its extended slide
Earlier this year, the company projected organic sales growth of 10% to 11% for 2025. However, as the actual growth rate came in at 19.5%, investors viewed the outlook as underwhelming. Management has since made multiple downward revisions to its 2026 guidance, including a May adjustment citing reduced adoption of its Watchman heart implant procedures. CEO Michael Mahoney indicated that revenue growth may remain flat in the second and third quarters.
Why the stock’s lofty price target may not last
Though analyst sentiment has turned cautious, 27 of 31 analysts covering the stock maintain buy ratings. The consensus price target of $78 per share implies a 65% potential upside. However, achieving this target may be difficult given current forward valuations in the mid-teens, which align with peers like Abbott Laboratories and Medtronic. A re-rating would likely require accelerated growth, but weaker-than-expected Q2 results could push targets lower.
Should you buy stock in Boston Scientific right now?
Potential investors should weigh the risks carefully. While the stock trades at a comparable valuation to industry peers, ongoing guidance revisions and declining procedural volumes present challenges. A rebound in growth or positive operational updates could support recovery, but the path to $78 per share remains uncertain.
